358 related articles for article (PubMed ID: 21946259)
1. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report.
Chen ML; Shah VP; Crommelin DJ; Shargel L; Bashaw D; Bhatti M; Blume H; Dressman J; Ducharme M; Fackler P; Hyslop T; Lutter L; Morais J; Ormsby E; Thomas S; Tsang YC; Velagapudi R; Yu LX
Eur J Pharm Sci; 2011 Nov; 44(4):506-13. PubMed ID: 21946259
[TBL] [Abstract][Full Text] [Related]
2. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report.
Chen ML; Shah VP; Crommelin DJ; Shargel L; Bashaw D; Bhatti M; Blume H; Dressman J; Ducharme M; Fackler P; Hyslop T; Lutter L; Morais J; Ormsby E; Thomas S; Tsang YC; Velagapudi R; Yu LX
AAPS J; 2011 Dec; 13(4):556-64. PubMed ID: 21845486
[TBL] [Abstract][Full Text] [Related]
3. The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference.
Chen ML; Blume H; Beuerle G; Davit B; Mehta M; Potthast H; Schug B; Tsang YC; Wedemeyer RS; Weitschies W; Welink J
Eur J Pharm Sci; 2018 Jan; 111():153-157. PubMed ID: 28964950
[TBL] [Abstract][Full Text] [Related]
4. Generic drug product equivalence: current status.
Meyer MC
Am J Manag Care; 1998 Aug; 4(8):1183-9; quiz 1190-2. PubMed ID: 10182892
[TBL] [Abstract][Full Text] [Related]
5. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
Brodniewicz-Proba T
Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
[TBL] [Abstract][Full Text] [Related]
6. United States Food and Drug Administration requirements for approval of generic drug products.
Meyer MC
J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
[TBL] [Abstract][Full Text] [Related]
7. The need for additional metrics to assess therapeutic equivalence of some multiphasic modified-release products.
Kondra PM; Endrenyi L; Tothfalusi L
Clin Ther; 2011 Sep; 33(9):1214-9. PubMed ID: 21849209
[TBL] [Abstract][Full Text] [Related]
8. Current status of the international comparator (reference) product system.
Idänpään-Heikkilä JE
Eur J Drug Metab Pharmacokinet; 2000; 25(1):36-7. PubMed ID: 11032088
[TBL] [Abstract][Full Text] [Related]
9. Variability and impact on design of bioequivalence studies.
Van Peer A
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
[TBL] [Abstract][Full Text] [Related]
10. Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence?
Dupont AG; Heller F
Acta Clin Belg; 2009; 64(5):406-14. PubMed ID: 19999388
[TBL] [Abstract][Full Text] [Related]
11. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation.
Jiang W; Kim S; Zhang X; Lionberger RA; Davit BM; Conner DP; Yu LX
Int J Pharm; 2011 Oct; 418(2):151-60. PubMed ID: 21803144
[TBL] [Abstract][Full Text] [Related]
12. Summary report of second EUFEPS/AAPS conference on global harmonization in bioequivalence.
Chen ML; Blume H; Beuerle G; Mehta M; Potthast H; Brandt A; Schug BS; Ducharme M; Endrenyi L; Gallicano K; Schuirmann D; Welink J
Eur J Pharm Sci; 2019 Jan; 127():24-28. PubMed ID: 30342171
[TBL] [Abstract][Full Text] [Related]
13. Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified-release products: workshop summary report.
Chen ML; Shah VP; Ganes D; Midha KK; Caro J; Nambiar P; Rocci ML; Thombre AG; Abrahamsson B; Conner D; Davit B; Fackler P; Farrell C; Gupta S; Katz R; Mehta M; Preskorn SH; Sanderink G; Stavchansky S; Temple R; Wang Y; Winkle H; Yu L
Eur J Pharm Sci; 2010 May; 40(2):148-53. PubMed ID: 20347972
[TBL] [Abstract][Full Text] [Related]
14. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
15. Statistical and regulatory considerations in assessments of interchangeability of biological drug products.
Tóthfalusi L; Endrényi L; Chow SC
Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S5-11. PubMed ID: 24832831
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the bioavailability and bioequivalence of generic medications.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127
[TBL] [Abstract][Full Text] [Related]
17. Current regulatory approaches of bioequivalence testing.
Karalis V; Macheras P
Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
[TBL] [Abstract][Full Text] [Related]
18. [Bioequivalence studies of pharmaceutical preparations].
Vetchý D; Frýbortová K; Rabisková M; Danecková H
Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
[TBL] [Abstract][Full Text] [Related]
19. Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India.
Lee SL; Saluja B; García-Arieta A; Santos GM; Li Y; Lu S; Hou S; Rebello J; Vaidya A; Gogtay J; Purandare S; Lyapustina S
AAPS J; 2015 Sep; 17(5):1285-304. PubMed ID: 26002510
[TBL] [Abstract][Full Text] [Related]
20. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.
Meredith PA
Curr Med Res Opin; 2009 Sep; 25(9):2179-89. PubMed ID: 19601710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
